Imfinzi is only immunotherapy to demonstrate overall survival at three years in unresectable stage III non-small cell lung cancer

This article was originally published here

These latest results show a durable and sustained OS benefit in patients with unresectable, Stage III NSCLC who had not progressed following concurrent chemoradiation therapy (CRT), a previous

The post Imfinzi is only immunotherapy to demonstrate overall survival at three years in unresectable stage III non-small cell lung cancer appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply